This article is more than 5 years old. Information may no longer be current.

VIDEO: Clinical trials show similarities between ranibizumab, aflibercept in treating DME

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

SEATTLE — At the Association for Research in Vision and Ophthalmology meeting, Marco A. Zarbin, MD, PhD, discusses a review of randomized clinical trials of anti-VEGF agents for treating diabetic macular edema, including RISE, RIDE, VIVID, VISTA, RESTORE, Protocol T and Protocol S. The review found that both aflibercept and ranibizumab were "equally effective" in inducing a two-step regression in diabetic retinopathy, durability of the anti-VEGFs was "almost identical," and incidence of systemic side effects "was comparable" in all the studies, Zarbin said.